Summary Safety Review - Alpha Lipoic Acid - Assessing the Potential Risk of Low Blood Sugar (Hypoglycemic Episodes)

This safety review was carried out by Health Canada after the publication of case reports of IAS (insulin autoimmune syndrome) causing hypoglycemic episodes linked with the use of oral alpha lipoic acid products in individuals with a genetic variation which causes the body's own defence system to attack insulin (insulin autoimmune syndrome).

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 17:48 (UTC)
Created April 17, 2026, 17:48 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2017-05-18 00:00:00
open_canada_keywords {"fr": ["Examen sommaire de l'innocuité", "acide alpha-lipoïque", "évaluation", "risque potentiel", "hypoglycémie", "épisodes hypoglycémiques", "syndrome auto-immun à l'insuline", "acide alpha-lipoïque oral", "système de défense de l'organisme", "insuline"], "en": ["Summary Safety Review", "Alpha Lipoic Acid", "assessing", "potential risk", "Low Blood Sugar", "Hypoglycemic Episodes", "insulin autoimmune syndrome", "oral alpha lipoic-acid", "body's own defence-system", "insulin"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Résumé de l'examen de l'innocuité - Acide alpha-lipoïque - Évaluation du risque de baisse du taux de sucre dans le sang (épisodes hypoglycémiques)
update_frequency as_needed